Navigation Links
Direct induction of chondrogenic cells from human dermal fibroblast culture by defined factors
Date:10/19/2013

A research team led by Professor Noriyuki Tsumaki of the Center for iPS Cell Research and Application (CiRA) at Kyoto University and Dr. Hidetatsu Ohtani, a former CiRA member who now works as a post doctoral fellow at Osaka University Graduate School of Medicine, has succeeded in directly converting human dermal fibroblasts into induced chondrogenic cells (iChon cells) without passing through an iPS cell stage in a process known as direct reprogramming. This finding has been published in PLOS ONE on October 16, 2013.

Articular cartilage, which is made up of chondrocytes and extracellular material in the form of Type II, Type IX, and Type XI collagens and aggrecan, fulfills the functions of ensuring smooth joint movement and absorbing shocks. Cartilage has little regenerative capacity and is gradually lost due to injury, aging, and other factors.

Normal articular cartilage consists of hyaline cartilage, but when this is lost it is partially replaced by fibrous cartilage. Fibrous cartilage produces Type I collagen and loses the extracellular material structure specific to cartilage. To restore cartilage function, this means that either high-purity hyaline cartilage not containing fibrous cartilage must be prepared and transplanted into the site where cartilage has been lost, or fibrous cartilage must be converted in situ into hyaline cartilage.

One conceivable method of producing cartilage would be to induce it from iPS cells. Alternatively, if it were possible to convert fibroblasts directly into chondrocytes without an intermediate iPS cell stage, chondrocytes could probably be produced in a shorter period of time than via an iPS cell-based method.

In 2011, Professor Tsumaki and his team reported that, by inserting into mouse dermal fibroblasts two reprogramming factors (c-MYC and KLF4) and one cartilage factor (SOX9), they had achieved direct reprogramming into induced chondrogenic cells without passing through an iPS cell stage. In the present study, the team confirmed that, by inserting the same three factors (c-MYC, KLF4, and SOX9) into human dermal fibroblasts, it was possible to directly generate iChon cells (Fig. 1). The iChon cells had lost the gene pattern specific to fibroblasts and instead displayed the gene pattern of chondrocytes. Additionally, when the iChon cells were transplanted to immunodeficient mice, they generated hyaline cartilage tissue (Fig.2), and no formation of teratomas or other tumors was observed for three months after the iChon cells were transplanted.

The present study demonstrates that direct reprogramming of fibroblasts into chondrocytes is also possible in human cells. Because the method used in the study makes use of c-MYC, which is thought to have a major role in tumorigenesis, and because it employs a retrovirus to introduce the factors, it could not be applied without modification in human therapy.

To produce chondrocytes for cartilage regeneration, CiRA also has the option of using the iPS cell stock which it is now engaged in building. Using the iPS cell stock would involve not autologous transplantation but isogeneic (allogeneic) transplantation, and rejection reaction and other risks would therefore need to be considered, but it would also have major cost benefits.

Another application of direct reprogramming is to carry out direct reprogramming of fibrous cartilage into hyaline cartilage in vivo. For this purpose, scientists will need to develop a technology to induce local reprogramming around cartilage tissue that avoids gene transduction, for instance by using chemical compounds instead. Going forward, a careful distinction will need to be drawn in applying the two methods use of the iPS cell stock and use of the direct reprogramming method.

The researchers hope that the technique developed in this study will represent one option for supply of high-purity chondrocytes for cartilage regeneration, and that it will contribute to elucidation of the pathology of cartilage-related diseases.


'/>"/>

Contact: Akemi Nakamura
cira-pr@cira.kyoto-u.ac.jp
81-753-667-000
Center for iPS Cell Research and Application - Kyoto University
Source:Eurekalert  

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. InspireMD Elects Sol J. Barer, Ph.D. Chairman of the Board of Directors
3. Michael Cusumano, MITs Sloan Distinguished Professor of Management, Joins Quantum Leap Innovations Board of Directors
4. BioStorage Technologies Appoints New Member to Board of Directors
5. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
6. Fate Therapeutics Announces the Appointment of William H. Rastetter as Chairman of its Board of Directors and Interim CEO
7. Ecology Coatings Develops Coatings Safe for Direct Contact with Food Products
8. Sinovac Announces Resignation of Chup Hung Mok from Board of Directors
9. Robert Farrell Joins Bionovos Board of Directors
10. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
11. Berkeley Lab Director Paul Alivisatos wins Wolf Prize in Chemistry
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Direct induction of chondrogenic cells from human dermal fibroblast culture by defined factors
(Date:4/26/2017)... ... April 26, 2017 , ... ... for phase I clinical trials comes to Tampa, San Francisco and Boston in ... professionals representing FDA regulated organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., ...
(Date:4/26/2017)... , April 26, 2017  Genisphere LLC, ... platform, has signed a collaborative and sponsored research ... Silvia Muro . The overall goal of ... pharmacodynamics of various 3DNA designs and formulations after ... targeting diseases of the vasculature as well as ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew Terzella, ... duties on May 15, 2017. , Dr. Terzella completed his residency in Physical ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... recognized outstanding manufactures in 10 categories with over 30 nominees and well as ... Manufacturing presented the new award and the event was hosted by CompanyWeek and ...
Breaking Biology Technology:
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/16/2017)... , March 16, 2017 CeBIT 2017 - Against identity fraud with ... Reading ... Used combined in one project, multi-biometric solutions provide a crucial ... Used combined in ... ...
Breaking Biology News(10 mins):